salmeterol xinafoate |
94749-08-3 |
Salmetedur |
Arial |
GR 33343X xinafoate |
Salmeterol 1-hydroxy-2-naphthoate |
SALMETEROLO |
Salmeterol (xinafoate) |
4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate |
GR 33343 G |
2-(hydroxymethyl)-4-1-hydroxy-2-6-(4-phenylbutoxy)hexylaminoethylphenol;1-hydroxynaphthalene-2-carboxylic acid |
Serevent diskus |
MFCD00897708 |
NCGC00094372-03 |
Asmerole |
Betamican |
Dilamax |
Inaspir |
Ultrabeta |
Beglan |
DSSTox_CID_25798 |
DSSTox_RID_81137 |
DSSTox_GSID_45798 |
Serevent Inhaler and Disks |
Salmeterolxinafoate |
SMR000875207 |
CAS-94749-08-3 |
Salmeterol xinafoate USAN:USP |
Serevent (TN) |
4-1-Hydroxy-2-6-(4-phenylbutoxy)hexylaminoethyl-2-(hydroxymethyl)phenol 1-Hydroxy-2-naphthoate |
SCHEMBL18070 |
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha-diol 1-hydroxy-2-naphthoate (salt) |
MLS001332577 |
MLS001332578 |
CHEBI:9012 |
LIPO-202 |
CHEMBL1082607 |
DTXSID1045798 |
C36H45NO7 |
Salmeterol xinafoate (JAN/USP) |
HMS2232I16 |
HMS3263K22 |
HMS3676P13 |
HMS3749I03 |
HMS3885J19 |
AMY23373 |
BCP04778 |
Tox21_111270 |
Tox21_501100 |
s4296 |
AKOS016004957 |
Tox21_111270_1 |
CCG-270203 |
CS-1527 |
GR-33343 G |
KS-1140 |
LP01100 |
NCGC00015938-05 |
NCGC00094372-01 |
NCGC00094372-02 |
NCGC00094372-04 |
NCGC00261785-01 |
(+/-) 4-Hydroxy-a1-6-(4-phenylbutoxy)hexylaminom-ethyl-1,3-benzenedimethanol xinafoate |
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt) |
HY-17453 |
BCP0726000003 |
AB0020656 |
DB-057527 |
EU-0101100 |
FT-0642283 |
V1621 |
Salmeterol xinafoate, >=98% (HPLC), solid |
D00687 |
R10007 |
A916443 |
SR-01000597359 |
Q-201697 |
SR-01000597359-1 |
Q27264747 |
Salmeterol xinafoate, European Pharmacopoeia (EP) Reference Standard |
Salmeterol xinafoate, United States Pharmacopeia (USP) Reference Standard |
4-Hydroxy-alpha-({6-(4-phenylbutoxy)hexylamino}methyl)-1,3-benzenedimethanol xinafoate |
Salmeterol xinafoate for system suitability, European Pharmacopoeia (EP) Reference Standard |
Salmeterol Xinafoate, Pharmaceutical Secondary Standards; Certified Reference Material |
4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate |
4-Hydroxy-?1-6-(4-phenylbutoxy)hexylaminomethyl-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid salt |